A 52-week, Multi-center, Open Label, Single Arm, Phase 3 Study to Evaluate the Efficacy and Safety of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients

Trial Profile

A 52-week, Multi-center, Open Label, Single Arm, Phase 3 Study to Evaluate the Efficacy and Safety of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Hepatitis B immune globulin (Primary)
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Sponsors SK Chemicals
  • Most Recent Events

    • 20 Apr 2016 According to a SK Plasma media release, the company announced results from this trial of human hepatitis B immunoglobulin for prevention of recurrence of hepatitis B in liver transplant patients.
    • 29 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 09 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top